Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection

Hepatocellular carcinoma (HCC) is a common and deadly malignancy that is increasing in incidence in developed countries. The emergence of hepatitis C virus (HCV) accounts for about half of this increase in HCC, although the etiology of HCC in 15%‐50% of new HCC cases remains unclear. The most common form of chronic liver disease in developed countries is nonalcoholic fatty liver disease (NAFLD), which encompasses a broad spectrum of histopathology. The prevalence of NAFLD, including the more aggressive nonalcoholic steatohepatitis (NASH), is increasing with the growing epidemics of diabetes and obesity. NASH can progress to cirrhosis and its related complications. Growing evidence suggests that NASH accounts for a large proportion of idiopathic or cryptogenic cirrhosis, which is associated with the typical risk factors for NASH. HCC is a rare, although important complication of NAFLD. Diabetes and obesity have been established as independent risk factors for the development of HCC. New evidence also suggests that hepatic iron deposition increases the risk of HCC in NASH‐derived cirrhosis. Multiple case reports and case reviews of HCC in the setting of NASH support the associations of diabetes and obesity with the risk of HCC, as well as suggest age and advanced fibrosis as significant risks. Insulin resistance and its subsequent inflammatory cascade that is associated with the development of NASH appear to play a significant role in the carcinogenesis of HCC. The complications of NASH, including cirrhosis and HCC, are expected to increase with the growing epidemic of diabetes and obesity. (HEPATOLOGY 2010;51:1820–1832)

[1]  V. Castranova,et al.  JNK1, a potential therapeutic target for hepatocellular carcinoma. , 2009, Biochimica et biophysica acta.

[2]  S. Harrison,et al.  NASH and HCC. , 2009, Clinics in liver disease.

[3]  S. Caldwell,et al.  Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[4]  K. Shimada,et al.  Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. , 2009, Atherosclerosis.

[5]  V. Alves,et al.  Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? , 2009, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[6]  Y. Hiasa,et al.  Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Michael L. Johnson,et al.  Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. , 2009, Gastroenterology.

[8]  V. Castranova,et al.  Beyond apoptosis of JNK1 in liver cancer , 2009, Cell cycle.

[9]  P. Micheli,et al.  Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. , 2009, Journal of hepatology.

[10]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  Xianglin Shi,et al.  Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. , 2009, Journal of hepatology.

[12]  A. Pietrangelo Iron in NASH, chronic liver diseases and HCC: how much iron is too much? , 2009, Journal of hepatology.

[13]  H. Nakagawa,et al.  Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH , 2009, Gut.

[14]  M. Czaja,et al.  Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance , 2009, Hepatology.

[15]  M. Taniai,et al.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.

[16]  S. Caldwell,et al.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology , 2009, Journal of Gastroenterology.

[17]  E. Wagner,et al.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.

[18]  G. Chejfec,et al.  Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? , 2008, Archives of pathology & laboratory medicine.

[19]  Z. Younossi,et al.  Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. , 2008, Journal of hepatology.

[20]  S. Taylor-Robinson,et al.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. , 2008, World Journal of Gastroenterology.

[21]  N. Kato,et al.  Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  Ramesh Natarajan,et al.  Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[23]  Z. Younossi,et al.  6 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH HIGHER OVERALL MORTALITY AND LIVER RELATED MORTALITY , 2008 .

[24]  M. Ziol,et al.  Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. , 2008, Gastroenterology.

[25]  A. McCullough The Epidemiology and Risk Factors of NASH , 2007 .

[26]  M. Mori,et al.  Primary liver cancers with nonalcoholic steatohepatitis , 2007, European journal of gastroenterology & hepatology.

[27]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[28]  S. Ikeya,et al.  [Two cases of patients with hepatocellular carcinoma (HCC) that developed in cryptogenic cirrhosis suggestive of nonalcoholic steatohepatitis (NASH) as background liver disease after clinical courses of 26 years]. , 2007, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[29]  T. Luedde,et al.  Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma , 2007 .

[30]  Z. Younossi,et al.  Epidemiology and natural history of NAFLD and NASH. , 2007, Clinics in liver disease.

[31]  E. Bugianesi,et al.  Non-alcoholic steatohepatitis and cancer. , 2007, Clinics in liver disease.

[32]  Kenichi Kobayashi,et al.  Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis , 1992, Gastroenterologia Japonica.

[33]  T. Luedde,et al.  Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. , 2007, Cancer cell.

[34]  K. Eguchi,et al.  Two cases of non‐alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis , 2006, Journal of gastroenterology and hepatology.

[35]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[36]  T. Saibara,et al.  7. 非アルコール性脂肪肝炎 (NASH) の診断と治療 , 2006 .

[37]  M. Karin,et al.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Maehara,et al.  Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. , 2006, Gastroenterology.

[39]  M. Czaja,et al.  Jnk1 but not jnk2 promotes the development of steatohepatitis in mice , 2006, Hepatology.

[40]  Tetsuji Sato,et al.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. , 2006, Annals of internal medicine.

[41]  D. Schuppan,et al.  EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. , 2005, Biochemical pharmacology.

[42]  Shi-yao Chen,et al.  Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. , 2005, Journal of hepatology.

[43]  Y. Ueda,et al.  Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid , 2005, Virchows Archiv.

[44]  Y. Yoon,et al.  Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[46]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[47]  Candy S. Lee,et al.  Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Crespo,et al.  Non-alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma , 2005, Obesity surgery.

[49]  M. Manos,et al.  Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease , 2005, Hepatology.

[50]  A. Suzuki,et al.  Chronological development of elevated aminotransferases in a nonalcoholic population , 2005, Hepatology.

[51]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[52]  David A. Sass,et al.  Nonalcoholic Fatty Liver Disease: A Clinical Review , 2005, Digestive Diseases and Sciences.

[53]  K. Wakasa,et al.  Hepatocellular Carcinoma Arising from Nonalcoholic Steatohepatitis: Report of Two Cases , 2005, Surgery Today.

[54]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[55]  M. Taniai,et al.  Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH , 2004, Journal of Gastroenterology.

[56]  S. Caldwell,et al.  Obesity and hepatocellular carcinoma. , 2004, Gastroenterology.

[57]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[58]  D. Lobo,et al.  Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. , 2004, Journal of hepatology.

[59]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[60]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[61]  A. Luciani,et al.  Carcinome hépatocellulaire en l’absence de cirrhose au cours d’une stéato-hépatite non alcoolique , 2004 .

[62]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[63]  S. Kihara,et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. El‐Serag,et al.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.

[65]  E. Abdalla,et al.  Obesity and diabetes as a risk factor for hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[66]  A. Luciani,et al.  [Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis]. , 2004, Gastroenterologie clinique et biologique.

[67]  H. Adami,et al.  A prospective study of obesity and cancer risk (Sweden) , 2004, Cancer Causes & Control.

[68]  John K. Wiencke,et al.  Impact of race/ethnicity on molecular pathways in human cancer , 2004, Nature Reviews Cancer.

[69]  Teruaki Kimura,et al.  Hepatocellular carcinoma with nonalcoholic steatohepatitis , 2004, Journal of Gastroenterology.

[70]  P. Hayashi,et al.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.

[71]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[72]  K. Eguchi,et al.  Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.

[73]  Jian-Gao Fan,et al.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. , 2003, World journal of gastroenterology.

[74]  N. Kennedy,et al.  Role of JNK in Tumor Development , 2003, Cell cycle.

[75]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[76]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[77]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[78]  Z. Younossi,et al.  Nonalcoholic fatty liver disease (NAFLD) two decades later: are we smarter about its natural history? , 2003, American Journal of Gastroenterology.

[79]  J. Marrero,et al.  NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States , 2002, Hepatology.

[80]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[81]  S. Lai,et al.  Epidemiology of Fatty Liver in a Hospital-based Study in Taiwan , 2002, Southern medical journal.

[82]  M. Tang,et al.  The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. , 2002, Carcinogenesis.

[83]  Hajime Isomoto,et al.  Fatty liver in non‐alcoholic non‐overweight Japanese adults: Incidence and clinical characteristics , 2002, Journal of gastroenterology and hepatology.

[84]  O. Ukkola,et al.  Adiponectin: a link between excess adiposity and associated comorbidities? , 2002, Journal of Molecular Medicine.

[85]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[86]  G. Loss,et al.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.

[87]  J. Ludwig,et al.  Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. , 2002, Journal of hepatology.

[88]  P. Giral,et al.  Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.

[89]  J. Patrie,et al.  Is NASH underdiagnosed among African Americans? , 2002, American Journal of Gastroenterology.

[90]  G. Pacini,et al.  Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.

[91]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[92]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[93]  Z. Younossi,et al.  Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[94]  L. Bianchi,et al.  Liver biopsy in elevated liver functions tests? An old question revisited. , 2001, Journal of hepatology.

[95]  P. D. James,et al.  Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. , 2001, Journal of hepatology.

[96]  H. El‐Serag,et al.  The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans , 2001, American Journal of Gastroenterology.

[97]  Y. Matsuzawa,et al.  Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .

[98]  K. Tsuneyama,et al.  Hepatocellular carcinoma arising in non‐alcoholic steatohepatitis , 2001, Pathology international.

[99]  K. Yamazaki,et al.  Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. , 2001, Journal of submicroscopic cytology and pathology.

[100]  Sue Goo Rhee,et al.  Hydrogen Peroxide: A Key Messenger That Modulates Protein Phosphorylation Through Cysteine Oxidation , 2000, Science's STKE.

[101]  P. Thuluvath,et al.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.

[102]  R. Paraná,et al.  Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? , 2000, American Journal of Gastroenterology.

[103]  H. Adami,et al.  Role of diabetes mellitus in the etiology of hepatocellular carcinoma. , 2000, Journal of the National Cancer Institute.

[104]  H. Zhu,et al.  Mitochondrial adaptations to obesity-related oxidant stress. , 2000, Archives of biochemistry and biophysics.

[105]  M. Blumenkehl Response to Dr. Kirsch , 2000, American Journal of Gastroenterology.

[106]  V. de Lédinghen,et al.  Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. , 2000, Journal of hepatology.

[107]  H. Cortez‐Pinto,et al.  Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.

[108]  T. Ben-Menachem,et al.  Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients , 1999, American Journal of Gastroenterology.

[109]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[110]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[111]  H. Cortez‐Pinto,et al.  Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.

[112]  P. Ward,et al.  Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.

[113]  M Linet,et al.  Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.

[114]  S. Finkelstein,et al.  Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[115]  E. Schmidt,et al.  Biological effects of human insulin receptor substrate‐1 overexpression in hepatocytes , 1997, Hepatology.

[116]  C. Christoffersen,et al.  Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor , 1997, Diabetologia.

[117]  H. Adami,et al.  Excess risk of primary liver cancer in patients with diabetes mellitus. , 1996, Journal of the National Cancer Institute.

[118]  Y. Ahn Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. , 1996, Gut.

[119]  G. Rassidakis,et al.  Histopathology of chronic hepatitis C in relation to epidemiological factors. , 1996, Journal of hepatology.

[120]  F. J. Farrell,et al.  Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[121]  J. Ludwig,et al.  Two cases from the spectrum of nonalcoholic steatohepatitis. , 1995, Journal of clinical gastroenterology.

[122]  K. Ishak,et al.  Histopathology of Hepatitis C Virus Infection , 1995, Seminars in liver disease.

[123]  J. Olsen,et al.  Obesity and cancer risk: a Danish record-linkage study. , 1994, European journal of cancer.

[124]  A. Czaja,et al.  Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. , 1993, Gastroenterology.

[125]  E. Schiff,et al.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1993, Gastroenterology.

[126]  S. Sherlock,et al.  The pathology of hepatitis C , 1992, Hepatology.

[127]  F. Schaffner,et al.  The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis , 1992, Hepatology.

[128]  B. Cesana,et al.  Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis , 1992, Hepatology.

[129]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[130]  H. Nomura,et al.  Prevalence of fatty liver in a general population of Okinawa, Japan. , 1988, Japanese journal of medicine.

[131]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[132]  Ground Ke Liver pathology in aircrew. , 1982 .

[133]  K. E. Ground Liver pathology in aircrew. , 1982, Aviation, space, and environmental medicine.

[134]  C P Price,et al.  Liver disease in patients with diabetes mellitus. , 1980, Postgraduate medical journal.

[135]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[136]  L. Garfinkel,et al.  Variations in mortality by weight among 750,000 men and women. , 1979, Journal of chronic diseases.

[137]  P. Christoffersen,et al.  Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties. , 1977, Scandinavian journal of gastroenterology.